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Osteoblasts are an important component of the
hematopoietic microenvironment in bone. However,
the mechanisms by which osteoblasts control hema-
topoiesis remain unknown.We show that augmented
HIF signaling in osteoprogenitors results in HSC
niche expansion associatedwith selective expansion
of the erythroid lineage. Increased red blood cell
production occurred in an EPO-dependent manner
with increased EPO expression in bone and sup-
pressed EPO expression in the kidney. In contrast,
inactivation of HIF in osteoprogenitors reduced
EPO expression in bone. Importantly, augmented
HIF activity in osteoprogenitors protected mice
from stress-induced anemia. Pharmacologic or
genetic inhibition of prolyl hydroxylases1/2/3 in
osteoprogenitors elevated EPO expression in bone
and increased hematocrit. These data reveal an
unexpected role for osteoblasts in the production
of EPO and modulation of erythropoiesis. Further-
more, these studies demonstrate a molecular role
for osteoblastic PHD/VHL/HIF signaling that can be
targeted to elevate both HSCs and erythroid progen-
itors in the local hematopoietic microenvironment.INTRODUCTION
The bone marrow is a complex and dynamic microenvironment
with multiple cells types contributing to ‘‘niches’’ that support
HSCs, myelopoiesis, and lymphopoiesis in the bone marrow
(Calvi et al., 2003; Kiel et al., 2005; Me´ndez-Ferrer et al., 2010).
Among these cell types, osteoblasts play an important role in
regulating multiple hematopoietic lineages. Conditional ablationof osteoblasts in adult mice showed that osteoblasts are
required to maintain hematopoiesis in the bone marrow. An early
loss of hematopoietic stem cells as well as committed progenitor
cells of the B-lymphocyte and erythroid lineages indicated that
osteoblasts contribute to the regulation of multiple hematopoi-
etic lineages (Visnjic et al., 2004). Several groups have shown
a correlation between osteoblasts and HSC numbers in the
bone marrow (Calvi et al., 2003; Zhang et al., 2003). Additionally,
osteoblasts directly regulate thematuration and differentiation of
B-lymphocytes (Wu et al., 2008). Whether osteoblasts directly or
indirectly contribute to the regulation of erythroid progenitors in
the bone marrow remains unknown. In addition to playing a
physiologic role in the regulation of hematopoiesis, osteoblasts
have also been identified as an important therapeutic target for
stem-cell-based therapies (Adams et al., 2007). However, little
is known regarding the mechanisms by which osteoblasts
support hematopoiesis. Understanding the molecular mecha-
nisms governing osteoblastic control of hematopoiesis will allow
for the development of novel therapeutic strategies for the treat-
ment of hematologic disorders.
Osteoblasts express components of the HIF signaling
pathway under physiologic and pathophysiologic conditions,
indicating that HIF signaling is an important mediator of normal
osteoblast function and disease. The central components of
the HIF signaling pathway are the prolyl hydroxylase enzymes 1,
2, and 3 (PHD1/2/3); VHL; HIF-1; and HIF-2. The PHDs and VHL
negatively regulate the pathway under normoxic conditions by
cooperatively targeting hypoxia-inducible transcription factors
HIF-1 and HIF-2 for proteasomal degradation (Semenza, 2001).
Under hypoxic conditions, HIF-1 and HIF-2 are stabilized and
coordinate the cellular response to hypoxia by activating gene
expression programs that facilitate oxygen delivery and cellular
adaptation to oxygen deprivation (Semenza, 2001). In addition
to hypoxia, growth factor signaling also activates HIF activity in
osteoblasts through the PI3K/AKT pathway (Akeno et al., 2002).
In many cell types, activation of the PI3K/AKT pathway increases
HIF activity in an mTOR-dependent manner that is thought toCell 149, 63–74, March 30, 2012 ª2012 Elsevier Inc. 63
Figure 1. Generation of Mice Deficient for VHL or HIF-1 and HIF-2
in Osteoblasts
(A–C) ROSA-LacZ reporter expression of Osterix-Cre (A and B) in 8-week-old
mouse tibia. Arrows in (A) point to osteoblasts at the endosteal bone surface
and embedded in cortical bone with B-galactosidase activity. (B) Shows the
absence of detectable B-galactosidase activity in ROSA-LacZ mice without
OSX-Cre. (C) Arrows point to subset of hypertrophic chondrocytes expressing
B-galactosidase activity.
(D) Efficient recombination of the Vhlh, Hif-1, and Hif-2 alleles in the bone of
Osterix-Cre mutant mice. PCR analysis of genomic DNA isolated from bone of
(1) OSX-Cre control, (2) OSX-VHL, (3) OSX-Cre control, and (4) OSX-HIF-1/
HIF-2 mice. The following abbreviations are used: 2-lox, conditional allele;
1-lox, recombined allele; and WT, wild-type allele.
(E) Immunohistochemical analysis of HIF-1 (top) and HIF-2 (bottom) expres-
sion in OSX-Cre tibias. Arrows point to osteoblasts expressing HIF-1 or HIF-2.have both transcriptional and posttranslational effects on HIF.
Thus, multiple stimuli activate HIF signaling to maintain cellular
survival and homeostasis under stress conditions.
HIF signaling in osteoblasts plays an important role in bone
formation and homeostasis. Conditional ablation of HIF-1 and
HIF-2 in osteoblasts causes a reduction in bone volume,
whereas HIF-1 and HIF-2 overstabilization leads to an increase
in bone mass. The changes in bone volume were largely associ-
ated with modulation of bone vascularization and VEGF expres-
sion revealing an important role for HIF signaling in osteoblasts in
coupling osteogenesis with angiogenesis (Wang et al., 2007).
HIF signaling also regulates hematopoiesis. Hematopoietic
stem cell (HSC) metabolism is dependent on glycolysis. This
process is regulated at least in part through the transcriptional
activation of Meis1 by HIF-1 (Simsek et al., 2010). Additionally,
dysregulation of HIF-1 affects HSC cell-cycle quiescence and
numbers. Deletion of HIF-1 in HSCs resulted in a loss of HSC
quiescence and numbers during stress conditions demon-
strating a direct role for HIF in the regulation of HSCs (Takubo
et al., 2010). HIF signaling also regulates mature hematopoietic
lineages. Most notably, HIF-1 was purified as the factor respon-
sible for the hypoxic induction of EPO and regulates erythropoi-
esis during development and under stress (Semenza and Wang,
1992; Yoon et al., 2006; Yu et al., 1999). In addition to HIF-1,
HIF-2 also regulates EPO in adult mice (Haase, 2010). HIF-1
and HIF-2 control EPO expression in the fetal liver and kidney
to promote erythroid progenitors cell viability, proliferation, and
differentiation (Haase, 2010). Additionally, HIF signaling directly
promotes erythroid progenitor survival (Flygare et al., 2011).
Here we have utilized genetic and pharmacologic mouse
models of constitutive HIF activation and inactivation in osteo-
progenitor cells to investigate the role of HIF signaling in osteo-
blastitic control of hematopoiesis. We show that osteoblasts
produce EPO through a HIF-dependent mechanism under phys-
iologic and pathophysiologic conditions both in vitro and in vivo.
Importantly, we found that modulation of the PHD/VHL/HIF
pathway in osteoblasts is sufficient to induce EPO in bone,
elevate hematocrit, and protect mice from stress-induced
anemia. Additionally, augmented HIF activity in osteoblasts
increases functional hematopoietic stem cells and early progen-
itors in the bone marrow. These data reveal osteoblasts as
a previously unsuspected source of endogenous EPO and iden-
tify the PHD/VHL/HIF pathway in osteoblasts as a therapeutic
target to elevate EPO and HSCs in the local hematopoietic
microenvironment.
RESULTS
Generation of Mice with HIF-1 and HIF-2
Overstabilization and Inactivation in Osteoprogenitor
Cells
Osteoblasts are an essential component of bone and the bone
marrow microenvironment for the regulation of skeletal and
hematopoietic homeostasis. They express two HIF-a homologs
(HIF-1a and HIF-2a) that have been previously shown to regulate
HIF target gene expression and control skeletal homeostasis
(Wang et al., 2007). In order to define the role of HIF signaling
in osteoblasts in the regulation of hematopoiesis, we condition-64 Cell 149, 63–74, March 30, 2012 ª2012 Elsevier Inc.ally inactivated VHL, HIF-1, and HIF-2 in osteoprogenitor cells.
For this purpose, mice homozygous for the Vhlh, Hif-1, and
Hif-2 conditional alleles (2-lox) were crossed to mice expressing
Cre-recombinase under the control of the osterix promoter
(OSX-Cre) to generate OSX-VHL and OSX-HIF-1/HIF-2 mice
(Gruber et al., 2007; Haase et al., 2001; Rodda and McMahon,
2006; Ryan et al., 1998).
Osterix-Cre is a well-characterized transgene that mediates
efficient Cre-recombinase activity in osteoprogenitor cells,
thereby targeting the entire osteoblastic lineage (Rodda and
McMahon, 2006). The specificity of OSX-Cre in adult bone was
confirmed with ROSA-LacZ reporter mice. Specific b-galactosi-
dase activity was found in all cells of the osteoblastic lineage
including endosteal osteoblasts, osteoblasts, and stromal cells
located at the chondro-osseous junction (Figures 1A–1C). As
previously reported, OSX-Cre activity was also found in a subset
of hypertrophic and columnar chondrocytes (Figure 1C) (Maes
et al., 2010b). Most importantly, OSX-Cre activity was absent
from all hematopoietic cells in the bone marrow (Figure 1A).
Figure 2. Augmented HIF Activity in Osteo-
blasts through VHL Deletion Expands the
HSC Niche
(A) Histological analysis of H&E stained OSX-Cre
tibias at 8 weeks of age.
(B and C) Histomorphometric analysis of trabec-
ular bone volume (BV/TV) and trabecular number
(Tb.N) in tibia (n = 6).
(D) H&E stained tibia at 8 weeks of age.
(E and F) Histomorphometric analysis of trabecular
bone volume (BV/TV) and trabecular number
(Tb.N) in OSX-Cre tibias (n = 6).
(G) Flow cytometric analysis (FACS) of c-Kit+ Lin-
eagelow Sca-1+ (KLS) progenitors in OSX-Cre bone
marrow.
(H) Frequency of KLS in OSX-Cre mutant bone
marrow shown as percentage of total bone
marrow cells at 8-weeks-of age (K, n = 7 in each
group).
(I) FACS analysis of multipotent progenitor (MPP)
and KLS-SLAM (HSC) of 8-week-old OSX-Cre
bone marrow.
(J) Frequency of MPPs in OSX-Cre bone marrow
shown as percentage of total bone marrow cells.
For each group analyzed n = 4.
(K) Frequency of HSCs in OSX-Cre bone marrow
shown as percentage of total bone marrow cells.
For each group analyzed n = 4. FACS experiments
shown are a representative experiment in which
littermate controls were directly compared to OSX
mutant mice. All experiments were independently
performed at least three times. See also Figure S1.
All data are represented as mean ± standard error
of the mean (SEM).Osterix-Cre mediates efficient recombination of the Vhlh,
Hif-1, and Hif-2 conditional alleles. The Vhlh conditional allele
contains LoxP sites flanking the Vhlh promoter and exon 1, re-
sulting in complete loss of Vhlh expression andHIF overstabiliza-
tion upon Cre-mediated recombination (Haase et al., 2001).
Efficient recombination of the VHL conditional allele in OSX-
VHL tibiae was observed by genomic PCR analysis for the
recombined (1-lox) allele (Figure 1D). Consistent with VHL inac-
tivation, we observed an increase in the number of osteoblasts
and the intensity of nuclear HIF-1 and HIF-2 expression in
OSX-VHL tibias by immunohistochemical analysis (Figure 1E).
The conditional alleles for Hif-1 and Hif-2 contain Lox-P sites
flanking exon 2 (which encodes the DNA-binding domain) result-
ing in an out-of-frame deletion of exon 2 and loss of HIF-1 and
HIF-2 expression following Cre recombination (Gruber et al.,
2007; Ryan et al., 1998). Osterix-Cre-mediated recombination
of the Hif-1 and Hif-2 conditional alleles was readily detectable
in adult OSX-HIF-1/HIF-2 tibias and resulted in a reduction of
HIF-1 and HIF-2 protein in osteoblasts (Figures 1D and 1E).
Augmented HIF Activity in Osteoprogenitors Expands
the HSC Niche in the Bone Marrow
Previous reports have demonstrated that osteoblasts are a crit-
ical component of the HSC niche. Specifically, an increase intrabecular osteoblastic cells and trabeculae are associated
with an increase in HSCs (Calvi et al., 2003; Zhang et al.,
2003). Therefore, we first analyzed the functional consequences
of HIF-1 and HIF-2 overstabilization on trabecular bone and HSC
homeostasis. OSX-VHL mutant mice exhibited excessive accu-
mulation of trabecular bone in the metaphyseal and diaphyseal
regions of the long bones (Figure 2A). Increased trabeculae
were associated with increased trabecular osteoblasts as indi-
cated by increased expression of the osteoblastic marker
collagen type I throughout the long bone (Figure S1A, available
online). Stromal cells and dilated blood vessels filled with red
blood cells surrounded the trabeculae (Figure 2A). Hypervascu-
larization in OSX-VHLmutant bones was apparent as staining for
CD31 revealed an increase in blood vessels throughout the bone
(Figure S1B). This increase in vascularization was associated
with a significant increase in local vascular endothelial growth
factor (VEGF) production by osteoblasts (Figure S1C). However,
circulating levels of VEGF in serum remained unaffected (Fig-
ure S1D). Histomorphometry revealed a 2.5-fold increase in
trabecular bone volume in the metaphyseal region associated
with an significant increase in trabecular number (Figures 2B
and 2C). To determine whether HIF signaling in osteoblasts is
required to maintain trabecular bone homeostasis in VHL-defi-
cient mice, we generated and analyzed OSX-VHL/HIF1/HIF2Cell 149, 63–74, March 30, 2012 ª2012 Elsevier Inc. 65
triple knockout mice. In contrast to OSX-VHL mutants, OSX-
VHL/HIF1/HIF2 mice had significantly reduced trabecular bone
volume and number compared to littermate controls (Figures
2D–2F). These data demonstrate that augmented HIF activity
in osteoprogenitors expands trabecular bone volume associated
with increased vascularization.
To determine whether HIF signaling in osteoprogenitors
affects the composition of hematopoietic cells within the bone
marrow, we first compared hematopoietic progenitor and HSC
composition in 8-week-old OSX-Cre mutant mice. Because
OSX-VHLmice were significantly smaller than littermate controls
and total bone marrow cell numbers were decreased, the anal-
ysis of hematopoietic lineages in OSX mutant mice is reported
as a percent frequency of bone marrow cells (data not shown).
We analyzed the early KLS (cKithigh Lineagelow Sca1+) pro-
genitors that include HSCs and multipotent progenitors (MPP).
Strikingly, the frequency of KLS cells within OSX-VHL bone
marrow was increased 3-fold compared to littermate controls
(Figures 2G and 2H). The frequency of KLS in OSX-VHL/HIF-1/
HIF-2 mutants was comparable to OSX-CNTRL mutants
demonstrating that KLS frequency in OSX-VHL bone marrow is
controlled by HIF activity (Figure 2H). Within the KLS population
of OSX-VHL mutants, we observed a significant increase in
the frequency of both MPP (CD150CD48) and HSC
(CD150+CD48) populations (Figures 2I–2K). These immuno-
phenotypic findings suggest that VHL deletion and enhanced
HIF activity in osteoprogenitor cells leads to an increased
frequency of HSCs in the bone marrow.
To functionally test whether HSCs are increased in OSX-VHL
bone marrow, we performed long-term repopulation assays.
Whole bone marrow from OSX-CNTRL or OSX-VHL mice (male
FVB) was mixed 1:1 with wild-type competitor marrow (female
FVB) and transplanted into lethally irradiated recipient mice
(female FVB). The contribution to peripheral blood and B cells
in the bone marrow was assessed at 20 weeks following
transplantation. Real time PCR analysis of SRY chromosome
expression revealed a significant increase in Y chromosome
expression in both the peripheral blood and B220+ B cells
from mice transplanted with OSX-VHL donor marrow compared
to mice transplanted with OSX-CNTRL marrow (Figures S1E
and S1F). Together, these findings indicate cells isolated from
the VHL-deficient bone marrow microenvironment contain an
increased frequency of HSCs capable of reconstituting irradi-
ated recipients.
Selective Expansion of the Erythroid Lineage
in OSX-VHL Mutant Mice Leads to the Development
of HIF-Dependent Polycythemia
We next examined whether augmented HIF signaling in osteo-
progenitors affects the ability of osteoblasts to support mature
blood lineages. We compared cells of the myeloid and lymphoid
lineages in peripheral blood from 8-week-old mice OSX-Cre
mutant mice. OSX-VHL mutant mice exhibited significant
changes in the numbers of red blood cells and lymphocytes.
Red blood cell numbers were increased from 10 ± 0.4 in OSX-
Controls to 16 ± 1.4 in OSX-VHL mice, whereas lymphocyte
numbers were decreased from 6,819 ± 2,211 in controls to
1,596 ± 845 in OSX-VHL mutants (Figure 3A). Increased RBC66 Cell 149, 63–74, March 30, 2012 ª2012 Elsevier Inc.and decreased lymphocyte numbers in OSX-VHL mutant mice
were HIF dependent as OSX-VHL/HIF-1/HIF-2 mutants had
similar numbers of RBCs and lymphocytes compared to OSX-
Control mice (Figure 3A). These data reveal that osteoblastic
HIF affects both erythroid and lymphoid homeostasis.
Given that a direct role for osteoblasts in the regulation of
erythropoiesis has not been previously reported, we sought to
further investigate the role of the HIF signaling pathway osteo-
blasts for the regulation of erythropoiesis. One hundred percent
of OSX-VHL mutant developed severe polycythemia by
2 months of age. Polycythemia in OSX-VHLmice was character-
ized by redness of the paws, splenomegaly, extramedullary
erythropoiesis, elevated hematocrit (the average was 73%
compared to 45% in controls), and red blood cell numbers
(Figures 3A–3E). To examine whether the development of
polycythemia in OSX-VHL mice was HIF-1 and/or HIF-2 depen-
dent, we analyzed OSX-VHL/HIF-1, OSX-VHL/HIF-2, and OSX-
VHL/HIF-1/HIF-2 mice. Hematocrit values in OSX-VHL/HIF-2
and OSX-VHL/HIF-1/HIF-2 mice were indistinguishable from
controls, whereas OSX-VHL/HIF-1 mutants exhibited a similar
increase in hematocrit (70%) compared to OSX-VHL mutants
(Figure 3E). These data show that augmented HIF-2 sig-
naling in osteoprogenitor cells leads to the development of
polycythemia.
To examine themechanisms for HIF-mediated polycythemia in
OSX-VHLmutants, we performed a detailed analysis of themye-
loerythroid compartment in OSX-VHL bone marrow (Pronk et al.,
2007). Flow-cytometric analysis showed no significant difference
in myeloid progenitor KLS (cKithigh Lineagelow Sca1); granulo-
cyte-macrophage progenitors (GMP, KLS FcgRII/IIIhigh
CD150); premegakaryocyte-erythroid, pre-erythroid,megakar-
yocyte (Pre-MegE/MkP/Pre-CFU-E, KLS FcgRII/IIIlow CD150+)
or mature megakaryocyte (Mk, KLS CD41+) cells within OSX-
VHL bone marrow (Figures 3F–3I). In contrast, CD71+ Ter119+
erythroid progenitors were significantly increased in OSX-VHL
bone marrow (1.4-fold) and spleen (4-fold, Figures 3J–3L).
Consistent with the immunophenotyping results, hematopoietic
progenitor colony assays showed a significant and specific
increase in mature erythroid (CFU-E) compared to immature
erythroid (BFU-E) progenitors in OSX-VHL bonemarrow (Figures
3Mand 3N) (Wu et al., 1995). These results demonstrate that VHL
deletion in osteoprogenitors causes a specific expansion of the
erythroid lineage.
Increased Hematocrit in OSX-VHL Mice Is EPO
Dependent and Associated with Increased EPO
Expression in Bone and Decreased EPO Expression
in the Kidney
The glycoprotein EPO is the primary hormone responsible for
the regulation of erythropoiesis. Clinically EPO overproduction
results in the development of polycythemia. EPO protein levels
were significantly increased in the sera from polycythemic
OSX-VHL and OSX-VHL/HIF-1 mice compared to EPO levels
in littermate control mice (Figure 4A). Inactivation of HIF-1/
HIF-2 or HIF-2, but not HIF-1, in OSX-VHL mice significantly
reduced EPO levels demonstrating that HIF-2 is the predomi-
nant HIF required for dysregulated EPO production in OSX-
VHL mice (Figure 4A). Thus, augmented HIF-2 signaling in
Figure 3. Selective Expansion of the Erythroid Lineage in OSX-VHL Mice Leads to the Development of HIF-Dependent Polycythemia
(A) CBC analysis of peripheral blood from 8-week-old OSX-Cre mutant mice (n = 8 for all groups except n = 6 for OSX-VHL/HIF-1/HIF-2).
(B) Photograph of paws of 8-week-old OSX-VHL and littermate control (OSX-CNTRL).
(C) Photograph of spleens collected from 8-week-old OSX-CNTRL (left) and OSX-VHL (right) mice.
(D) Histological analysis of spleen from OSX-Cre mice at 403 (top) and 2003 (bottom).
(E) Average hematocrit (HCT) of OSX-Cre mice at 8-weeks-of age (CNTRL, n = 8; VHL, n = 8; VHL/HIF-1, VHL/HIF-2, VHL/HIF-1/HIF-2, n = 6).
(F–I) Frequency of myeloid progenitor KLS (cKithigh Lineagelow Sca1); granulocyte-macrophage progenitors (GMP, KLS FcgRII/IIIhigh CD150);
premegakaryocyte-erythroid, pre-erythroid, megakaryocyte (Pre-MegE/MkP/Pre-CFU-E, KLS FcgRII/IIIlow CD150+) and mature megakaryocyte (Mk, KLS
CD41+) cells within OSX-CNTRL and OSX-VHL bone marrow (n = 4 for all groups).
(J) FACS analysis of erythroid lineage CD71+ Ter119+ in bone marrow and spleen of OSX-Cre mice.
(K and L) Significant increase in the frequency of erythroid progenitors in OSX-VHLmutant bonemarrow (K, n = 4 in each group) and spleen (L, n = 3 in each group)
as determined by FACS analysis.
(M and N) Quantification of CFU-E (n = 5) and BFU-E (n = 3) colonies in the bone marrow of OSX-mice. FACS experiments shown are a representative experiment
in which littermate controls were directly compared to OSX mutant mice. All experiments were independently performed at least three times. Data are repre-
sented as mean ± SEM.
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Figure 4. Increased Hematocrit in OSX-VHL Mice
Develops in an EPO-Dependent Manner Associ-
ated with Increased EPO Expression in Bone and
Decreased EPO Expression in the Kidney
(A) Analysis of EPO protein levels in the serum of 8-week-
old OSX-mice determined by ELISA (CNTRL, VHL/HIF-1,
VHL/HIF-2, and VHL/HIF-1/HIF-2, n = 6; VHL, n = 8).
(B) Soluble EPO-receptor therapy (EPO-R) significantly
reduces hematocrit in OSX-VHLmice. Average hematocrit
of 6.5-week-old OSX-Cre mice treated with adenovirus
expressing FC control or soluble EPO-R. Statistical
significant differences (p < 0.05) in hematocrit were
observed between VHL-FC and CNTRL-FC-treated mice
(*) as well as VHL-FC and VHL-EPOR-treated (#) mice
(n = 4 each group).
(C) Real time PCR analysis of EPO mRNA expression in
tissues collected from 8-week-old OSX-Cre mice (n = 4
mice per group).
(D) Real time PCR analysis of EPO expression in bone
marrow stromal cells isolated from OSX-Cre hindlimbs
(n = 3 mice per group). Data are represented as mean ±
SEM. See also Figure S2.osteoprogenitor cells leads to polycythemia associated with
elevated circulating EPO.
To determine whether the development of polycythemia in
OSX-VHL mutant mice is EPO dependent, we utilized a soluble
EPO-receptor therapy (EPO-R) to block the functional activity
of circulating EPO. Soluble EPO-R was delivered via an adeno-
viral system in which the liver produces systemic soluble
EPO-receptor that effectively decreases hematocrit in polycy-
themic mice for up to 28 days following tail vein injection
(Tam et al., 2006). When administered to OSX-VHL mutants
at 6.5 weeks of age, EPO-R completely prevented the develop-
ment of polycythemia in OSX-VHL mutants. Although OSX-VHL
FC control-treated mice exhibited significantly elevated
hematocrit (55%–60%) compared to OSX-CNTRL FC-treated
mice (41%); soluble receptor therapy significantly decreased
hematocrit both in OSX-VHL mice (22%) and OSX-CNTRL
mice (20%) after 21 days of therapy (Figure 4B). Accordingly,
the decrease in hematocrit in OSX-VHL EPO-R-treated
mice was associated with a significant decrease in CD71+
Ter119+ erythroid progenitors in the spleen compared to
OSX-VHL FC-Control-treated mice (Figure S2A). These data
demonstrate that the development of polycythemia and the
increase in erythroid progenitors in OSX-VHL mutants are
EPO dependent.
The kidney is the primary site for EPO production in adult
animals; however, the liver and brain can also produce levels
of EPO sufficient to induce polycythemia under stress conditions
(Haase, 2010). To confirm that Osterix-cre is not expressed in
tissues other than bone that may affect erythropoiesis or
produce EPO, we analyzed the efficiency of VHL recombination
in OSX-VHL kidney, liver, brain, and spleen. Although the recom-
bined VHL allele (1-lox) was readily detectable in the bone, the
recombined allele was not detected in the liver, kidney, or spleen
of OSX-VHL mice (Figure S2B). Interestingly, a weak signal for
the recombined VHL allele was detected in the brain, suggesting
that HIF signaling in the brain could contribute to regulation of
erythropoiesis in OSX-Cre mice (Figure S2B).68 Cell 149, 63–74, March 30, 2012 ª2012 Elsevier Inc.We next directly compared EPO mRNA expression in the
kidney, liver, brain, and bone of OSX-VHL and OSX-Control
mice. EPO levels in the kidney were suppressed in OSX-VHL
mice, ruling out the possibility that VHL deletion in the bone indi-
rectly augments renal EPO (Figure 4C). EPO mRNA was not de-
tected in the livers of OSX-VHL or OSX-Control mice, indicating
that reactivation of hepatic EPO does not occur in OSX-VHL
mutant mice (Figure 4C). Similarly, EPO levels in the brain were
not induced in OSX-VHLmutant mice (Figure 4C). Unexpectedly,
EPOwas highly expressed in OSX-VHL bone. Although EPOwas
not expressed at readily detectable levels in 8-week-old OSX-
Control bone, EPO was expressed in OSX-VHL bone at levels
significantly greater (6-fold) than those found in control kidneys
(Figure 4C).
Because total bone preparations from OSX-VHL mice contain
many cell types including VHL-deficient osteoblasts and chon-
drocytes, we directly assessed whether osteoblasts and/or
chondrocytes from OSX-VHL mice produce EPO. Primary
bone marrow stromal cells from postnatal day 3 OSX-VHL hin-
dlimbs expressed EPO at significantly higher levels than stromal
cells isolated from OSX-CNTRL bone marrow (Figure 4D). In
contrast, chondrocytes isolated from OSX-VHL growth plates
did not express higher levels of EPO in comparison to controls
(data not shown). These data suggest that VHL-deficient osteo-
blasts express EPO at levels capable at elevating serum EPO
and stimulating erythropoiesis.
Loss of HIF-2 in Osteoblasts Impairs EPO Expression
and Numbers of Erythroid Progenitors in the Bone
Marrow but Does Not Cause Anemia
To determine whether wild-type osteoblasts express EPO in
a HIF-dependent manner, we exposed primary calvarial osteo-
blast and bone marrow stromal cell cultures from wild-type
mice to 21% oxygen (normoxia) and 2% oxygen (hypoxia) to
induce HIF signaling in vitro. EPO expression in primary osteo-
blast cultures was significantly increased upon exposure to
hypoxia (Figure 5A). Inactivation of HIF-2 in OSX-HIF-2 mice
Figure 5. HIF-1 and HIF-2 Deletion in Osteoblasts Reduces EPO Expression and Erythroid Progenitors in the Bone but Does Not Cause
Anemia
(A) Real time PCR analysis of EPO expression in primary osteoblast cultures isolated from calvarie or bone marrow exposed to 21% or 2% oxygen (n = 5 each
group).
(B) Real time PCR analysis of EPO expression in neonatal hindlimbs (without growth plate) from OSX-CNTRL and OSX-HIF-2 mice (n = 4 each group).
(C and D) Frequency of erythroid progenitors in 8-week-old OSX-CNTRL and OSX-HIF-1/HIF-2 (C) and OSX-CNTRL and OSX-HIF-2 (D) bone marrow (L, n = 4
each group).
(E and F) Frequency of erythroid progenitors in 8-week-old OSX-CNTRL and OSX-HIF-1/HIF-2 (E) and OSX-CNTRL and OSX-HIF-2 (F) spleen (n = 4 each group).
(G) CBC analysis of peripheral blood from 8-week-old OSX-Cre mutant mice. n = 8 in each group.
(H) OSX-HIF-1/HIF-2 mice have a normal response to erythropoietic stress. Mice (n = 5 in each group) were injected with phenylhydrazine on days 0 and 1. The
proportion of reticulocytes in the red cell population was analyzed over 8 days. Corrected reticulocyte count (%) = reticulocyte count (%) X (hematocrit/45). Data
are represented as mean ± SEM. See also Figure S3.significantly reduced EPO expression in neonatal bone, indi-
cating that HIF-2 in osteoblasts drives EPO expression under
physiologic conditions in vivo (Figure 5B). In adult bones, EPO
expression was at the limit of detection in both OSX-CNTRL
and OSX-HIF-2 mice (data not shown).
To determine whether HIF signaling in osteoblasts contributes
to erythroid homeostasis, we analyzed the CD71+Ter119+
erythroid progenitor population in the bone marrow and spleen
of OSX-HIF-1/HIF-2 and OSX-HIF-2 mice. We observed a signif-
icant decrease in CD71+ Ter119+ cells in the bone marrow of
OSX-HIF-1/HIF-2 and OSX-HIF-2 mutants compared to litter-
mate controls (Figures 5C and 5D). In contrast, erythroid progen-
itors were not significantly changed in spleen of OSX-HIF-1/
HIF-2 or OSX-HIF-2 mutants (Figures 5E and 5F). These data
demonstrate that HIF signaling in osteoblasts has a physiological
role in the regulation of erythroid progenitors in the bonemarrow.
Additionally, HIF-1/HIF-2 deletion in OSX-HIF-1/HIF-2 mice re-
sulted in a significant decrease in trabecular bone volumeaccompanied by a reduced trend in hematopoieic progenitors
in the bone marrow, indicating that HIF signaling in osteoblasts
regulates bone and hematologic homeostasis under physiologic
conditions (Figure S3A–S3E).
Despite reduced erythroid progenitors in the bone marrow of
OSX-HIF-1/HIF-2 mice, adult mutants exhibited normal hemat-
ocrit and red blood cell numbers in peripheral blood (Fig-
ure 5G). This result may be explained by the low rate of eryth-
ropoiesis required to maintain hematocrit under homeostatic
conditions in adult mice. Therefore, we tested whether HIF
signaling in osteoprogenitors affects stress erythropoiesis by
using the phenylhydarzine (PHZ) model of hemolytic anemia.
OSX-CNTRL and OSX-HIF-1/HIF-2 mice were injected with
PHZ on days 0 and 1. Because the proportion of reticulocytes
in the red cell population allows for assessment of the erythro-
poietic rate (Socolovsky et al., 2001), reticulocytes were
analyzed at days 2, 5, and 8 following PHZ injection. After
PHZ treatment, reticulocytes dramatically increased andCell 149, 63–74, March 30, 2012 ª2012 Elsevier Inc. 69
Figure 6. Modulation of the PHD/VHL/HIF Pathway Is Sufficient to
Induce EPO Production in Adult Bone and Protect Mice from Anemia
(A) Augmented HIF signaling in osteoblasts protects mice from anemia.
Percent hematocrit in 8-week-old OSX-Cre mice 48 hr after initial phenyl-
hydrazine (PHZ) treatment (n = 5 in each group). * indicate a statically differ-
ence compared to untreated OSX-Control mice as determined by Students
t test (p < 0.05).
(B) Pharmacologic inhibition of PHDs induces EPO expression in adult bone.
EPO mRNA expression in 8-week-old bone 7 hr following intra-femoral
injection of saline or DMOG (n = 3 in saline and n = 3 in DMOG groups).
(C) Genetic inhibition of PHD1/2/3 activates Epo expression in bone. EPO
mRNA expression in 8 week old OSX-Cre mutant mice (n = 5 per group).
(D) Prolyl hydroxylase inhibition in osteoblasts increases hematocrit in 8-week-
old mice (n = 5 per group). Data are represented as mean ± SEM.reached a maximum at day 5 (Figure 5H). Reticulocyte counts
were not significantly different between OSX-CNTRL and OSX-
HIF-1/HIF-2 mutants (Figure 5H). These data suggest that HIF
signaling in osteoblasts contributes to the maintenance of
erythroid progenitor homeostasis in the bone marrow but is
not necessary to ensure normal hematocrit in either homeo-
static or stress conditions.
Modulation of the PHD/VHL/HIF Pathway in Osteoblasts
Is Sufficient to Induce EPO and Protect from Anemia
The findings above identify a role for HIF signaling in osteoblasts
in the regulation of EPO and erythroid progenitors, raising the
intriguing possibility that manipulation of the HIF pathway in
osteoblasts could be a therapeutic strategy for the treatment
of anemia. Therefore, we tested whether OSX-VHL mutant
mice with an increased serum EPO could be protected from
stress-induced anemia. In the PHZ model of hemolytic anemia,
OSX-Control mice developed an average hematocrit of 28%
within 48 hr of initial PHZ injection (Figure 6A). In contrast,
PHZ-treated OSX-VHL mice exhibited average hematocrit
values of 43%, which were comparable to untreated control
mice (Figure 6A). These data provide genetic evidence to
suggest that manipulation of HIF activity in osteoblasts is a ther-
apeutic strategy for anemia.
The prolyl hydroxylase enzymes PHD1, 2, and 3 (PHD1,2,3)
cooperate with VHL to target HIF-1 and HIF-2 for proteasomal70 Cell 149, 63–74, March 30, 2012 ª2012 Elsevier Inc.degradation. PHDs belong to a super family of 2 oxoglutarate-
dependent dioxygenases that require Fe2+, ascorbate, and
2-oxoglutarate for enzymatic activity (Kaelin and Ratcliffe,
2008). Several different classes of PHD inhibitors (PHI) have
shown efficacy in preclinical models of anemia and are in clinical
trials for the treatment of anemia (Hsieh et al., 2007; Murray et al.,
2010). To determine whether PHI inhibition is sufficient to acti-
vate EPO expression in bone, we treated adult mice with the
PHI dimethyloxallyl Glycine (DMOG). Local injection of DMOG
in bone resulted in a significant increase in EPO expression in
bone (Figure 6B). To determine whether PHD inhibition specifi-
cally in osteoblasts drives EPO expression, we generated mice
lacking PHD1,2,3 in osteoblasts using Osterix-Cre-mediated
recombination of the PHD1,2,3 floxed alleles (Takeda et al.,
2008). PHD1,2,3 deletion in osteoblasts dramatically increased
EPO in bone and hematocrit values (Figures 6C and 6D). The
induction of EPO expression in bone and hematocrit in OSX-
PHD1/2/3 mice was comparable to that observed in OSX-VHL
mice, demonstrating that PHD inhibition in bone phenocopies
VHL deletion in bone. Collectively, these results show that
manipulation of the PHD/VHL/HIF pathway in osteoblasts is
sufficient to induce EPO in bone, elevate hematocrit, and protect
mice from stress-induced anemia. These findings provide
preclinical evidence to indicate that targeting the PHD/VHL/HIF
pathway in the osteoblastic niche is a therapeutic strategy to
elevate EPO in the local hematopoietic microenvironment.
Furthermore, our findings indicate that the mechanism of action
for PHI-mediated EPO production in vivo may include EPO
production by osteoblasts.
DISCUSSION
In order to maintain erythroid homeostasis, EPO expression is
tightly regulated by developmental, physiological, and cell-
type-specific factors. During development, the source of EPO
switches from the fetal liver to the kidney where hypoxia and
HIF signaling are the primary stimulus for EPO production
(Haase, 2010). In response to acute anemia or hypoxia, hepato-
cytes can reactivate EPO expression (Kapitsinou et al., 2010). In
most other cell types, EPO expression is strongly repressed by
mechanisms that involve the GATA family of transcriptional
repressors (Obara et al., 2008). Notably, VHL has been inacti-
vated in over 13 distinct cell types in vivo and of these cell types,
only three, glial cells, hepatocytes, and renal interstitial cells,
have been reported to induce erythrocytosis (Kapitsinou and
Haase, 2008). Although the kidney and liver are the major
producers of EPO, EPO expression has also been reported in
the brain, lung, heart, spleen, and reproductive tract (Haase,
2010). Of these tissues, the brain is the only other tissue shown
to have the capacity to produce EPO that functionally regulates
erythropoiesis (Weidemann et al., 2009). Local EPO production
is thought to have a tissue protective effect by inducing antia-
poptotic effects, proliferation, differentiation, and survival
(Haase, 2010). Our findings reveal an unexpected source of
EPO within the hematopoietic microenvironment capable of
stimulating erythropoiesis (Figure 7). Although the kidney
remains the primary organ controlling hypoxia-driven EPO and
erythropoiesis, we demonstrate that activation of the HIF
Figure 7. The HIF Signaling Pathway in Osteoblasts Directly Modu-
lates Erythropoiesis through the Production of EPO and the Number
of HSCs
Osteoblasts produce EPO through a HIF-dependent mechanism under
physiologic and pathophysiologic conditions. Osteoblasts express HIF-1 and
HIF-2 that transcriptionally activate EPO expression. In conditions of
augmented HIF signaling (dashed line), osteoblasts produce both local and
systemic levels of EPO that stimulate erythropoiesis in the bone marrow and
spleen. Constitutive hyperactivation of HIF signaling leads to increased red
blood cells (RBC) and oxygen in the blood that feeds back to suppress renal
EPO production. Augmented HIF signaling in osteoblasts through VHL or
PHD1/2/3 inhibition is sufficient to drive EPO expression in adult bone, elevate
hematocrit, and protect mice from stress-induced anemia. Furthermore,
pharmacologic inhibition of PHDs via prolyl hydroxylase inhibitors (PHI) is
sufficient to activate EPO in adult bone. Additionally, augmented HIF activity in
osteoblasts expands HSCs indicating that therapeutic manipulation of the
PHD/VHL/HIF pathway in osteoblasts is a therapeutic strategy to elevate both
EPO and HSCs in the local hematopoietic microenvironment.pathway in osteoblasts protects mice from stress-induced
anemia. Here we identified an unexpected role for the PHD/
VHL/HIF signaling pathway in osteoblasts in the production of
EPO and modulation of erythropoiesis.
HIF overexpression in mature osteoblasts leads to aberrant
bone vascularization associated with augmented VEGF expres-
sion raising the possibility that enhanced VEGF may contribute
to some of the phenotypes observed in OSX-VHL mutants
(Wang et al., 2007). Constitutive VEGF expression in osteo-
chondroprogenitors leads to increased bone mass, aberrant
vascularization, and enhanced mobilization of hematopoietic
progenitors from the bone marrow. However, the number ofcirculating red or white blood cells were not changed in these
animals (Maes et al., 2010a). Although we cannot exclude the
possibility that augmented VEGF production may contribute to
bone accumulation and HSC expansion in OSX-VHL mutants,
we demonstrate that the development of polycythemia is EPO
dependent.
Consistent with previous findings, activation of the HIF
pathway led to a dramatic increase of trabecular bone (Wang
et al., 2007). In this study, we report that this increase in trabec-
ular bone is associated with an expansion of functional HSCs.
Our findings further highlight the important crosstalk between
bone and the hematopoietic compartment and reveal a role of
the HIF signaling pathway as component of this crosstalk. Inter-
estingly, lack of HIF signaling in osteoblasts did not significantly
affect HSC number in homeostatic conditions, although it altered
the bone compartment, suggesting that the relationship
between bone and hematopoiesis is complex and only partially
elucidated.
These findings have important clinical implications for the
treatment of anemia. Over 3 million patients suffer from anemia
as a result of renal insufficiency. Recombinant EPO and deriva-
tives are the standard therapy for the treatment of anemia.
Despite its clinical effectiveness, recombinant EPO therapy is
expensive, requires parenteral administration, and has the risk
of producing an antigenic response. For these reasons, efforts
are focused on developing cheaper, nonantigenic, and more
easily administered agents for the treatment of anemia. Small
molecule PHD inhibitors that pharmacologically activate the
HIF signaling pathway are currently in clinical trials for the treat-
ment of anemia. It is thought that these small molecule therapies
will revolutionize the treatment of anemia, bringing both conve-
nience and lower costs to millions of anemic patients (Yan
et al., 2010). However, the mechanism of action for these inhib-
itors is not completely understood. It has been hypothesized that
in patients with renal failure, the liver is the primary organ
producing EPO (Kapitsinou et al., 2010; Minamishima and Kae-
lin, 2010). Our data indicate that in addition to the liver, osteo-
blasts can also produce EPO and increase red blood cell
production after PHD inhibition (Figure 7). These findings are of
particular importance because we discovered that local produc-
tion of EPO by osteoblasts in the bone marrow microenviron-
ment is sufficient to drive erythropoiesis. Our pharmacological
approach unequivocally shows that EPO production can be
significantly upregulated in osteoblasts of adult wild-type mice.
Furthermore, augmented HIF activity in osteoblasts also drives
expansion of functional HSCs, which may provide additional
therapeutic benefits for anemic patients.EXPERIMENTAL PROCEDURES
Generation and Analysis of Mice
Generation of and genotyping analysis of the Vhlh, Hif-1, Hif-2, and Phd1/2/3
conditional mice and Osterix-Cre transgenic mice have been previously
described (Gruber et al., 2007; Haase et al., 2001; Rodda and McMahon,
2006; Ryan et al., 1998; Takeda et al., 2006). With the exception of bone
marrow transplantation studies, mice were generated in mixed C57/B6 and
FVB/N genetic backgrounds. Therefore, for all studies littermate Cre-recombi-
nase-positive heterozygous floxedmice and Cre-negative homozygous floxed
mice were used as controls. We found that the Osterix-Cre transgene did notCell 149, 63–74, March 30, 2012 ª2012 Elsevier Inc. 71
affect any of the phenotypes described in this manuscript. All procedures
involving mice were performed in accordance with the National Institutes of
Health (NIH) guidelines for use and care of live animals and were approved
by the Stanford University Institutional Animal Care and Use Committee.
PHI Inhibition in Bone with DMOG
We prepared 1.75 mg of DMOG in sterile saline and injected it directly into the
femur via standard procedures (Zhan and Zhao, 2008). Seven hours following
injection, mice were sacrificed and femurs were collected for RNA.
PHZ Stress Anemia Model
Mice were injected with 40mg/kg of PHZ in normal saline two times at 24 hr
intervals. Forty-eight hours after the initial injection, mice were bled to obtain
complete blood count (CBC) analysis and reticulocyte counts.
DNA and RNA Isolation
DNA was isolated according to Laird et al. (1991) and used for genomic PCR.
RNA was isolated with Trizol reagent according to manufacturer’s instructions
(Invitrogen).
Immunohistochemistry and Histological and Histomorphometric
Analysis
Hindlimbs from 8-week-old mice were dissected, fixed, decalcified, and
processed with standard procedures. HIF-1 was detected with the rabbit
anti-human/mouse HIF-1 polyclonal antibody (RD systems AB1536) at a
1:500 dilution. HIF-2 was detected with the rabbit anti-human/mouse HIF-2
polyclonal antibody (Novus NB100-122) at a dilution of 1:100. CD31 was
detected with CD31 (BD 550274) at a dilution of 1:200. All antibodies were
incubated overnight at 4C and developed with the TSA Biotin system (Per-
kin-Elmer) according to the manufacturer’s protocol.
Hematoxylin and eosin (H&E) staining was performed with standard
methods. Histomorphometric analysis of tibias was performed with the Os-
teomeasure system (Osteometrics) as previously described (Ohishi et al.,
2009).
B-galactosidase Staining
B-galactosidase stainingwas performed as previously described (Provot et al.,
2007).
Flow Cytometric Analysis
Fluorescence-activated cell sorting (FACS) analysis was performed on total
bone marrow and spleen cells. For analysis of the erythroid lineage, 1 3 106
cells were incubated with fluorescein isothiocyanate (FITC) anti-mouse
CD71 (ebioscience) and biotin anti-mouse Ter119 (ebioscience). For hemato-
poietic progenitors and HSCs, 4 3 106 cells were incubated with biotinylated
lineage antibodies (Ter119, B220, CD3, CD11b, and Ly-6G; ebiosience), FITC
anti-mouse c-Kit (ebioscience), phycoerythrin (PE) anti-mouse Sca-1, allophy-
cocyanin (APC) anti-mouse CD150 (TC15-12F12.2, Biolegend), Alexa Flour
700 anti-mouse CD48 (HM48-1, Biolegend), and eFlour 450 CD16/CD32 (93,
ebioscience).
Antibodies were incubated with cells for 30 min (erythroid lineage) or 60 min
(HSC/progenitors) in PBS containing 2% BSA on ice. Cells were washed three
times and incubated with Streptavidin-PE-Cy7 (ebioscience) for 30 min.
Samples were washed and data were collected on a LSRII (BD Bioscience).
Data were analyzed with FlowJo software (TreeStar). FACS experiments
shown are a representative experiment in which littermate controls were
directly compared to OSX mutant mice. All experiments were independently
performed at least three times.
Real Time PCR
Real time PCR was performed as previously described (Rankin et al., 2007).
For 18S amplification, cDNA was diluted 1:50. The primers used to amplify
specific target genes can be found in the Extended Experimental Procedures.
Generation and Production of Adenovirus
The production and purification of the EPO-receptor IgG2a-Fc adenoviruses
were performed as previously described (Tam et al., 2006); 6.5-week-old72 Cell 149, 63–74, March 30, 2012 ª2012 Elsevier Inc.OSX-VHL or OSX-CNTRL mice were bled for a baseline hematocrit at
day 1. At day 0, mice were injected with 13 108 pfu of the indicated adeno-
virus through the tail vein. Mice were bled once per week for 23 days following
injection.
CBC Analysis
CBC analysis was performed by the Department of Comparative Medicine at
Stanford University with an Abbott Cell-Dyn 3500 and by analysis of prepared
blood smears with a Wrights-Giemsa stain.
ELISA
VEGF and EPO ELISAs were performed according to manufacturer instruc-
tions with the exception that serumwas incubated in the ELISA plate overnight
at 4C (RandD Systems).
Primary Bone Marrow Stromal and Calvarial Osteoblast Isolation
Bone marrow stromal cells and calvarial osteoblasts from postnatal day 3 hin-
dlimbs were isolated by serial collagenase digestion as previously described
(Wu et al., 2008). Fractions 3–6 were plated in alphaMEM 10% FBS and incu-
bated under 21% or 2% oxygen for 4 days to reach confluency.
BFU-E and CFU-E Assays
Bonemarrowmononuclear and spleen cells were isolated and resuspended in
Iscove’s MDM 2% FBS. BFU-E and CFU-E assays were performed with
methocult M03434 and M03334, respectively, in triplicate according to manu-
facturer’s instructions (Stem Cell Technologies).
Statistical Analysis
Statistical analysis was performedwith Prism software (GraphPad). In all cases
a two-tailed, unpaired Student’s t test was performed to analyze statistical
differences between groups. p values < 0.05 were considered statistically
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at doi:10.1016/j.
cell.2012.01.051.
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